Standard

Novel biomarkers to detect occult cancer in patients with unprovoked venous thromboembolism : Rationale and design of the PLATO-VTE study. / Kraaijpoel, Noémie; Mulder, Frits I.; Carrier, Marc; van Lieshout, Annabel; Würdinger, Tom; Best, Myron G.; van Vlijmen, Bart J. M.; Mohammed, Yassene; Jara-Palomares, Luis; Kamphuisen, Pieter W.; di Nisio, Marcello; Ageno, Walter; Beyer-Westendorf, Jan; Vanassche, Thomas; Klokm, Frederikus A.; Otten, Hans-Martin; Peters, Mike J. L.; Cosmi, Benilde; Wolde, Marije ten; Bossuyt, Patrick M. M.; Büller, Harry R.; van Es, Nick.

In: Thrombosis Update, Vol. 2, 100030, 01.01.2021.

Research output: Contribution to journalArticleAcademicpeer-review

Harvard

Kraaijpoel, N, Mulder, FI, Carrier, M, van Lieshout, A, Würdinger, T, Best, MG, van Vlijmen, BJM, Mohammed, Y, Jara-Palomares, L, Kamphuisen, PW, di Nisio, M, Ageno, W, Beyer-Westendorf, J, Vanassche, T, Klokm, FA, Otten, H-M, Peters, MJL, Cosmi, B, Wolde, MT, Bossuyt, PMM, Büller, HR & van Es, N 2021, 'Novel biomarkers to detect occult cancer in patients with unprovoked venous thromboembolism: Rationale and design of the PLATO-VTE study', Thrombosis Update, vol. 2, 100030. https://doi.org/10.1016/j.tru.2020.100030

APA

Kraaijpoel, N., Mulder, F. I., Carrier, M., van Lieshout, A., Würdinger, T., Best, M. G., van Vlijmen, B. J. M., Mohammed, Y., Jara-Palomares, L., Kamphuisen, P. W., di Nisio, M., Ageno, W., Beyer-Westendorf, J., Vanassche, T., Klokm, F. A., Otten, H-M., Peters, M. J. L., Cosmi, B., Wolde, M. T., ... van Es, N. (2021). Novel biomarkers to detect occult cancer in patients with unprovoked venous thromboembolism: Rationale and design of the PLATO-VTE study. Thrombosis Update, 2, [100030]. https://doi.org/10.1016/j.tru.2020.100030

Vancouver

Author

Kraaijpoel, Noémie ; Mulder, Frits I. ; Carrier, Marc ; van Lieshout, Annabel ; Würdinger, Tom ; Best, Myron G. ; van Vlijmen, Bart J. M. ; Mohammed, Yassene ; Jara-Palomares, Luis ; Kamphuisen, Pieter W. ; di Nisio, Marcello ; Ageno, Walter ; Beyer-Westendorf, Jan ; Vanassche, Thomas ; Klokm, Frederikus A. ; Otten, Hans-Martin ; Peters, Mike J. L. ; Cosmi, Benilde ; Wolde, Marije ten ; Bossuyt, Patrick M. M. ; Büller, Harry R. ; van Es, Nick. / Novel biomarkers to detect occult cancer in patients with unprovoked venous thromboembolism : Rationale and design of the PLATO-VTE study. In: Thrombosis Update. 2021 ; Vol. 2.

BibTeX

@article{26ab988c189d428aa4c7e492365c7751,
title = "Novel biomarkers to detect occult cancer in patients with unprovoked venous thromboembolism: Rationale and design of the PLATO-VTE study",
abstract = "Occult cancer is detected in about 5% of patients with unprovoked venous thromboembolism (VTE) in the 12 months following VTE diagnosis. Current guidance suggests conducting a {\textquoteleft}limited{\textquoteright} cancer screening in these patients, consisting of medical history taking, physical examination, routine blood tests, chest X-ray, and age- and gender-specific testing, over full-body imaging. However, almost half of underlying cancers remain undetected with this approach. Blood-based liquid biopsies may provide an attractive addition or alternative to current cancer screening strategies, with a potentially higher detection rate while avoiding radiation or invasive testing. The PLATO-VTE study is an ongoing, investigator-initiated, multinational, prospective, observational cohort study comparing the sensitivity of novel biomarkers for detecting cancer with that of limited cancer screening in the setting of unprovoked VTE. Patients older than 40 years with a first episode of unprovoked VTE are eligible, while those with major and minor transient provoking risk factors for VTE are excluded. Patients undergo standard-of-care {\textquoteleft}limited{\textquoteright} cancer screening and are followed for 12 months for the occurrence of cancer. A blood sample for biomarker analysis is drawn within 10 days; a second sample is taken at 3 months to assess test result consistency over time. Three biomarkers are assessed: platelet mRNA, circulating tumor DNA, and plasma proteomics analysis. The sensitivity and predictive value of the biomarkers at baseline will be compared with those of limited screening. The results from the PLATO-VTE study may lead to reconsider current approaches for cancer screening in patients with unprovoked VTE.",
author = "No{\'e}mie Kraaijpoel and Mulder, {Frits I.} and Marc Carrier and {van Lieshout}, Annabel and Tom W{\"u}rdinger and Best, {Myron G.} and {van Vlijmen}, {Bart J. M.} and Yassene Mohammed and Luis Jara-Palomares and Kamphuisen, {Pieter W.} and {di Nisio}, Marcello and Walter Ageno and Jan Beyer-Westendorf and Thomas Vanassche and Klokm, {Frederikus A.} and Hans-Martin Otten and Peters, {Mike J. L.} and Benilde Cosmi and Wolde, {Marije ten} and Bossuyt, {Patrick M. M.} and B{\"u}ller, {Harry R.} and {van Es}, Nick",
year = "2021",
month = jan,
day = "1",
doi = "10.1016/j.tru.2020.100030",
language = "English",
volume = "2",
journal = "Thrombosis Update",
issn = "2666-5727",
publisher = "Elsevier BV",

}

RIS

TY - JOUR

T1 - Novel biomarkers to detect occult cancer in patients with unprovoked venous thromboembolism

T2 - Rationale and design of the PLATO-VTE study

AU - Kraaijpoel, Noémie

AU - Mulder, Frits I.

AU - Carrier, Marc

AU - van Lieshout, Annabel

AU - Würdinger, Tom

AU - Best, Myron G.

AU - van Vlijmen, Bart J. M.

AU - Mohammed, Yassene

AU - Jara-Palomares, Luis

AU - Kamphuisen, Pieter W.

AU - di Nisio, Marcello

AU - Ageno, Walter

AU - Beyer-Westendorf, Jan

AU - Vanassche, Thomas

AU - Klokm, Frederikus A.

AU - Otten, Hans-Martin

AU - Peters, Mike J. L.

AU - Cosmi, Benilde

AU - Wolde, Marije ten

AU - Bossuyt, Patrick M. M.

AU - Büller, Harry R.

AU - van Es, Nick

PY - 2021/1/1

Y1 - 2021/1/1

N2 - Occult cancer is detected in about 5% of patients with unprovoked venous thromboembolism (VTE) in the 12 months following VTE diagnosis. Current guidance suggests conducting a ‘limited’ cancer screening in these patients, consisting of medical history taking, physical examination, routine blood tests, chest X-ray, and age- and gender-specific testing, over full-body imaging. However, almost half of underlying cancers remain undetected with this approach. Blood-based liquid biopsies may provide an attractive addition or alternative to current cancer screening strategies, with a potentially higher detection rate while avoiding radiation or invasive testing. The PLATO-VTE study is an ongoing, investigator-initiated, multinational, prospective, observational cohort study comparing the sensitivity of novel biomarkers for detecting cancer with that of limited cancer screening in the setting of unprovoked VTE. Patients older than 40 years with a first episode of unprovoked VTE are eligible, while those with major and minor transient provoking risk factors for VTE are excluded. Patients undergo standard-of-care ‘limited’ cancer screening and are followed for 12 months for the occurrence of cancer. A blood sample for biomarker analysis is drawn within 10 days; a second sample is taken at 3 months to assess test result consistency over time. Three biomarkers are assessed: platelet mRNA, circulating tumor DNA, and plasma proteomics analysis. The sensitivity and predictive value of the biomarkers at baseline will be compared with those of limited screening. The results from the PLATO-VTE study may lead to reconsider current approaches for cancer screening in patients with unprovoked VTE.

AB - Occult cancer is detected in about 5% of patients with unprovoked venous thromboembolism (VTE) in the 12 months following VTE diagnosis. Current guidance suggests conducting a ‘limited’ cancer screening in these patients, consisting of medical history taking, physical examination, routine blood tests, chest X-ray, and age- and gender-specific testing, over full-body imaging. However, almost half of underlying cancers remain undetected with this approach. Blood-based liquid biopsies may provide an attractive addition or alternative to current cancer screening strategies, with a potentially higher detection rate while avoiding radiation or invasive testing. The PLATO-VTE study is an ongoing, investigator-initiated, multinational, prospective, observational cohort study comparing the sensitivity of novel biomarkers for detecting cancer with that of limited cancer screening in the setting of unprovoked VTE. Patients older than 40 years with a first episode of unprovoked VTE are eligible, while those with major and minor transient provoking risk factors for VTE are excluded. Patients undergo standard-of-care ‘limited’ cancer screening and are followed for 12 months for the occurrence of cancer. A blood sample for biomarker analysis is drawn within 10 days; a second sample is taken at 3 months to assess test result consistency over time. Three biomarkers are assessed: platelet mRNA, circulating tumor DNA, and plasma proteomics analysis. The sensitivity and predictive value of the biomarkers at baseline will be compared with those of limited screening. The results from the PLATO-VTE study may lead to reconsider current approaches for cancer screening in patients with unprovoked VTE.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85126121606&origin=inward

U2 - 10.1016/j.tru.2020.100030

DO - 10.1016/j.tru.2020.100030

M3 - Article

VL - 2

JO - Thrombosis Update

JF - Thrombosis Update

SN - 2666-5727

M1 - 100030

ER -

ID: 22154598